Product Information
STRIBILD TABLET is a brand product labeled by Gilead Sciences, Inc., priced at $150.1432 per EA under NDC 61958120101. Its NADAC has been published 663 times since Nov 28, 2013.
FDA first approved this application on Aug 27, 2012.
STRIBILD TABLET
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarateStrength
150; 150; 200; 300 mg/1; mg/1; mg/1; mg/1
Manufacturer
Gilead Sciences, Inc.NDC
61958120101
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATEApproval Type
New Drug (NDA)
FDA Application
NDA203100FDA Approved
8/27/2012
On Market Since
8/27/2012
Pharmacological Classes
Price Statistics
The NADAC for STRIBILD TABLET has been published 663 times since Nov 28, 2013, and over the history we have for it it has risen 98.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $150.1432 per EA |
|---|---|
| All-time high | $150.4090 (May 13, 2026) |
| All-time low | $75.4777 (Nov 28, 2013) |
| 52-week high | $150.4090 |
| 52-week low | $143.2323 |
| Median price | $110.0398 |
| Average price | $111.1186 |
| Largest weekly change | +6.9% (Jul 13, 2016) |
| Weeks tracked | 663 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Gilead Sciences, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cytochrome P450 3A Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of STRIBILD TABLET?
The current National Average Drug Acquisition Cost (NADAC) for STRIBILD TABLET, manufactured by Gilead Sciences, Inc., is $150.1432 per EA (NDC 61958120101), effective Sep 30, 2026.
How has the price of STRIBILD TABLET changed over time?
Over the history we have for it, the NADAC for STRIBILD TABLET has risen 98.9%. It has been tracked across 663 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for STRIBILD TABLET?
Since Nov 28, 2013, the NADAC for STRIBILD TABLET has ranged from a low of $75.4777 (Nov 28, 2013) to a high of $150.4090 (May 13, 2026), with a median of $110.0398 per EA.
Are there cheaper alternatives to STRIBILD TABLET?
No other NADAC-published product currently shares the active ingredient and strength of STRIBILD TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures STRIBILD TABLET?
STRIBILD TABLET (NDC 61958120101) is labeled by Gilead Sciences, Inc., and CMS classifies it as a brand product.